|
Developing of non-traditional antibiotics promises novel strategies to combat multidrug-resistant organism but would they work? Are the feasible to develop?
Topics discussed:
• The notion of non-traditional antibiotics as potential therapeutics against MDR organisms
• Increasing our understanding on the clinical efficacy of non-traditional antibiotics
• Regulatory pathways for approval of such compounds
Guest: Dr. John Rex, Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust.
Visit https://aac.asm.org to browse issues and/or submit a manuscript. |